BACKGROUND: A dramatic increase in morbidity and mortality from Clostridium difficile infection (CDI) due to the recent emergence of virulent, antibiotic-resistant strains has led to a search for alternatives to antibiotics, including vaccines and immune-based therapy that target the 2 key toxins-TcdA and TcdB. METHODS: We investigated the efficacy of specific human monoclonal antibodies (HuMab) and alpaca polyclonal antibodies against each toxin separately and in combination in the gnotobiotic piglet model of CDI. Additionally, the HuMab and polyclonal antibodies were exploited to investigate the precise contribution of each toxin to systemic and/or gastrointestinal (GI) tract disease. RESULTS: Our results indicate that TcdB is an important virulence factor associated with GI and systemic pathology. Administration of anti-TcdB antibody alone or with anti-TcdA protected 100% of piglets from development of systemic CDI and minimized GI lesions. Conversely, 100% of piglets administered only anti-TcdA developed severe GI and systemic disease, with 67%-83% fatality, faring worse than placebo-treated control animals. CONCLUSIONS: These results highlight the importance of TcdB in the pathogenesis of CDI and the effectiveness of TcdB-specific antibody in treating CDI. However, the results raise new questions regarding the nature of TcdA interaction with therapeutic antibodies.
BACKGROUND: A dramatic increase in morbidity and mortality from Clostridium difficileinfection (CDI) due to the recent emergence of virulent, antibiotic-resistant strains has led to a search for alternatives to antibiotics, including vaccines and immune-based therapy that target the 2 key toxins-TcdA and TcdB. METHODS: We investigated the efficacy of specific human monoclonal antibodies (HuMab) and alpaca polyclonal antibodies against each toxin separately and in combination in the gnotobiotic piglet model of CDI. Additionally, the HuMab and polyclonal antibodies were exploited to investigate the precise contribution of each toxin to systemic and/or gastrointestinal (GI) tract disease. RESULTS: Our results indicate that TcdB is an important virulence factor associated with GI and systemic pathology. Administration of anti-TcdB antibody alone or with anti-TcdA protected 100% of piglets from development of systemic CDI and minimized GI lesions. Conversely, 100% of piglets administered only anti-TcdA developed severe GI and systemic disease, with 67%-83% fatality, faring worse than placebo-treated control animals. CONCLUSIONS: These results highlight the importance of TcdB in the pathogenesis of CDI and the effectiveness of TcdB-specific antibody in treating CDI. However, the results raise new questions regarding the nature of TcdA interaction with therapeutic antibodies.
Authors: Sarah A Kuehne; Stephen T Cartman; John T Heap; Michelle L Kelly; Alan Cockayne; Nigel P Minton Journal: Nature Date: 2010-09-15 Impact factor: 49.962
Authors: Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino Journal: N Engl J Med Date: 2010-01-21 Impact factor: 91.245
Authors: Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood Journal: Nature Date: 2009-03-01 Impact factor: 49.962
Authors: Heather K Kroh; Ramyavardhanee Chandrasekaran; Zhifen Zhang; Kim Rosenthal; Rob Woods; Xiaofang Jin; Andrew C Nyborg; G Jonah Rainey; Paul Warrener; Roman A Melnyk; Benjamin W Spiller; D Borden Lacy Journal: J Biol Chem Date: 2017-11-27 Impact factor: 5.157
Authors: Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys Journal: Clin Vaccine Immunol Date: 2013-01-16
Authors: Peter Warn; Pia Thommes; Abdul Sattar; David Corbett; Amy Flattery; Zuo Zhang; Todd Black; Lorraine D Hernandez; Alex G Therien Journal: Antimicrob Agents Chemother Date: 2016-10-21 Impact factor: 5.191
Authors: Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng Journal: Infect Immun Date: 2014-12-08 Impact factor: 3.441
Authors: Pragya Rampuria; Gillian A Lang; T Scott Devera; Casey Gilmore; Jimmy D Ballard; Mark L Lang Journal: J Leukoc Biol Date: 2016-08-26 Impact factor: 4.962